Standpoint Research initiates coverage on Biogen Idec (Nasdaq: BIIB) with a Buy rating. Price target $70.

Standpoint analyst says, "The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE